Medical oxygen plant in Plainfield closing; 130 to lose jobs
Relocating operations to an existing plant in Canton, Ga., will result in the loss of 130 jobs.
Health Care Businesses
Articles
Lilly wins court ban on generic copy of Gemzar
Eli Lilly and Co. won a U.S. court ruling Wednesday that bars Teva Pharmaceutical Industries Ltd. from selling a generic version
of the cancer drug Gemzar until November.
Lilly drug wins U.K. backing as cancer therapy
Eli Lilly and Co.’s Alimta has received the preliminary backing of a United Kingdom agency as a maintenance treatment for
patients with the most common form of lung cancer.
Hill-Rom to cut 160 more jobs
The Batesville-based medical equipment supplier said it expects the cuts to save the company about $16 million a year.
Eli Lilly spent $2.2 M lobbying in 4th quarter
Lilly’s lobbying spending represents a 36-percent drop from the final quarter of 2008, even though the Congressional debate
over health care reform peaked during the last quarter of 2009.
Lilly to let 115 workers go in new outsourcing deal
Deal with unit of Massachusetts-based Thermo Fisher Scientific would keep many of the employees working in same
location.
Lilly eyes more animal-health acquisitions
Eli Lilly is interested in assets that may be offered for sale as a result of Sanofi-Aventis SA and Merck & Co.’s plan to
combine their veterinary units.
Bill kicks off years of change for local health care players
Sweeping changes phase in slowly for most, but insurers, hospitals, drug companies, employers, workers, medical device makers
and more will eventually feel impact.
Reform offers risk, opportunities for Lilly, WellPoint
Drugmakers and insurers could gain millions of customers under the legislation, but the industry also will pay new fees and
face stricter rules that may shrink profit and fuel mergers.
Congress passes historic health care bill
To pay for the changes, the legislation includes more than $400 billion in higher taxes over a decade, roughly half of it
from a new Medicare payroll tax on individuals with incomes over $200,000 and couples over $250,000.
Lilly sues to block generic of Adcirca lung treatment
Netherlands-based Synthon Pharmaceuticals is seeking U.S. Food and Drug Administration approval to sell a copy of the medicine.
IU incubator attracts East Coast biotech startup
Companion Diagnostics Inc. moves from Connecticut to the IU Emerging Technologies Center, hopes to create 30 high-paying jobs
by 2014.
Lilly victim of theft from Connecticut warehouse
Pharmaceuticals stolen Sunday morning could be worth up to $75 million.
Lilly pays $50M-plus for rights to testosterone lotion
Indianapolis-based Lilly will pay Acrux of West Melbourne, Australia, a $50 million license fee, plus $3 million when manufacturing
assets are transferred, but the deal could be worth millions more.
Health care software firm raises $1.15 million
Indianapolis-based PolicyStat LLC raised $1.15 million in angel capital from 31 individuals and Halo Capital Group.
WellPoint may be anti-competitive, Connecticut AG says
WellPoint Inc.’s Anthem Blue Cross & Blue Shield of Connecticut may constrain competition through contracts that require
that the insurer receives hospital discounts at least as favorable as any provided to a competitor.
Eli Lilly to buy European rights to Pfizer animal products
The acquisition will benefit Elanco, Lilly’s animal health division in Greenfield, which has become increasingly important
to Lilly as it braces for patent-protection losses.
Cornelius to retire as Bristol-Myers Squibb CEO
The former Guidant Corp. CEO and long-time Eli Lilly exec said he and his family will be returning to Indianapolis.
Lilly, Transition Therapeutics make diabetes deal
Drug developer Transition Therapeutics Inc. said Wednesday that it will pay $1 million to license a group of potential diabetes
drugs from Eli Lilly and Co.
Study: Hospital clout spurs higher Calif. health costs
While insurers get the blame for rising health-care costs for consumers, surging fees from hospitals and the growing dominance
of such providers may be just as responsible for driving up expenses, according to a new study examining California's
market.